Novartis's Sandoz strikes deal for biosimilar of Herceptin
30/04/2019 07:04
ZURICH, April 30 (Reuters) - Novartis's NOVN.S Sandoz
division has struck a deal with Taiwan's EirGenix Inc 6589.TWO
to market a biosimilar version of Roche's ROG.S Herceptin that
is now in late-stage development to treat some cancer tumours.
Novartis said the accord covers the trastuzumab biosimilar
in Phase III development for human epidermal growth factor
receptor 2 positive (HER2+) breast and gastric tumours.
EirGenix will be responsible for development and
manufacturing, while Sandoz has the right to commercialise the
product in all markets except China and Taiwan.
EirGenix will receive an upfront payment, milestone
payments, and a share of profits from sales, Novartis said,
giving no more financial details.
The deal - the third biosimilar collaboration for Sandoz in
18 months - expands the existing Sandoz cancer portfolio of four
oncology biosimilar medicines.
(Reporting by Michael Shields; editing by Jason Neely)
((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;))